Similar Items

Cover Image

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations. We assessed the effect of the GLP-1 receptor agonist dulaglutide on major...

Full description

Saved in:
Bibliographic Details
Institution:Universidad EIA
Main Authors: Gerstein, Hertzel C., Colhoun, Helen M., Dagenais, Gilles R., Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riesmeyer, Jeffrey S., Riddle, Matthew C., Rydén, Lars, Xavier, Denis, Messan Atisso, Charles, Dyal, Leanne, Hall, Stephanie, Rao-Melacini, Purnima, Wong, Gloria, Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C., Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas Matyas, Lanas, Fernando, Leiter, Lawrence A., Lopez-Jaramillo, Patricio, Cardona-Munoz, Ernesto German, Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J., Shaw, Jonathan E., Sheu, Wayne H-H., Temelkova-Kurktschiev, Theodora, The REWIND Investigators, Everest
Format: Artículo de revista
Language:English
Published: ELSEVIER 2019-07-13
Online Access:https://repositorio.udes.edu.co/handle/001/5694
Tags: Add Tag
No Tags, Be the first to tag this record!